The patient was instructed to prevent semaglutide and start dulaglutide once-weekly subcutaneous injections. No nodules are described within the 5 months since the patient stopped semaglutide and began dulaglutide.Observe renal functionality when initiating or escalating doses of WEGOVY in people reporting severe adverse gastrointestinal reactions.